GH Guardant Health, Inc.

Q3 2025 10-Q
Filed: Oct 29, 2025Period ending Sep 30, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR

Guardant Health, Inc. (GH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • No new risk factors added this quarter; no material changes since fiscal 2024 10-K filing
  • Most materially updated risk: none reported, risk factors unchanged since 2024 10-K
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$265M

+38.5% YoY +14.3% QoQ

Net Income

-$93M

+13.9% YoY +7.2% QoQ

Operating Margin

-37.3%

+2395bp YoY +852bp QoQ

Net Margin

-35.0%

+2131bp YoY +808bp QoQ

ROE

26.2%

Total Assets

$1.3B

EPS (Diluted)

$-0.75

+14.8% YoY +6.3% QoQ

Operating Cash Flow

-$35M

+30.6% YoY +41.3% QoQ

Source: XBRL data from Guardant Health, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Guardant Health, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.